Did anyone read the announcement of IMUC presenting at upcoming AARC meeting. Its seems as though they are preparing to move further along with the development of ICT-121. The news of pipeline growth and development has been outstanding recently. Shareholders will be well rewarded with the moves being made now.
Pretty ambitious undertaking, though they look like they will also test this against GBM, the markers (epitopes) work on many solid tumors - they're going for a general cancer vaccine as in their ICT-37 candidate. I'm not sure this is new news, ICT-121 is done for preclinical, maybe they'll announce enrollment for P!.
Yes, the announcement for additional trials is what I am anticipating. IMUC has established themselves well with the top research facilities in the country, this will make it much easier for them to enroll patients in trials and get hospitals on board. I believe their relationships made the enrollment for their current p2 trial faster than expected.